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Abstract
Background: Eosinophilic esophagitis (EoE) is characterized by the inflammation of the esophagus and the
infiltration of eosinophils into the esophagus, leading to symptoms such as dysphagia and stricture formation.
Systemic immune indicators like eotaxin and fibroblast growth factor were evaluated for possible synergistic
pathological effects. Moreover, blood cells, local tissue, and plasma from EoE and control subjects were studied to
determine if the localized disease was associated with a systemic effect that correlated with presence of EoE disease.
Method: Real-time polymerase chain reaction from peripheral blood mononuclear cells (PBMC),
immunohistochemistry from local esophageal biopsies, fluid assays on plasma, and fluorescence-activated cell
sorting on peripheral blood cells from subjects were used to study the systemic immune indicators in newly
diagnosed EoE (n = 35), treated EoE (n = 9), Gastroesophageal reflux disease (GERD) (n = 8), ulcerative colitis
(n = 5), Crohn’s disease (n = 5), and healthy controls (n = 8).
Result: Of the transcripts tested for possible immune indicators, we found extracellular signal-regulated kinase
(ERK), Bcl-2, bFGF (basic fibroblast growth factor), and eotaxin levels were highly upregulated in PBMC and
associated with disease presence of EoE. Increased FGF detected by immunohistochemistry in esophageal tissues
and in PBMC was correlated with low levels of pro-apoptotic factors (Fas, Caspase 8) in PBMC from EoE subjects.
Plasma-derived bFGF was shown to be the most elevated and most specific in EoE subjects in comparison to
healthy controls and disease control subjects.
Conclusion: We describe for the first time a possible mechanism by which increased FGF is associated with
inhibiting apoptosis in local esophageal tissues of EoE subjects as compared to controls. Eotaxin and FGF signaling
pathways share activation through the ERK pathway; together, they could act to increase eosinophil activation and
prolong the half-life of eosinophils in local tissues of the esophagus in EoE subjects.
Introduction
Eosinophilic esophagitis (EoE) is an inflammatory disor-
der of the esophagus that can be characterized by feed-
ing difficulties, heartburn, regurgitation, vomiting,
abdominal pain, dysphagia, and food impaction [1-3].
EoE seems to predominantly affect children, and in
particular, males [4]. Epidemiologic data from 2008 sug-
gest that in children the annual incidence of EoE is
approximately 1.3-1.6 per 10,000 and the prevalence is
approximately 4.3-9.1 per 10,000 [5,6]. Approximately
50% of subjects with EoE have co-existing atopic condi-
tions, such as food allergy, asthma, or eczema [7-12].
Food allergy is particularly prominent, but aeroallergens
also may play a role [13]. * Correspondence: knadeau@stanford.edu
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those of gastroesophageal reflux disease (GERD) and
initial illness may be thought to be GERD. However, the
symptoms do not resolve with gastric acid suppression,
and EoE presents with esophageal abnormalities during
endoscopy, showing eosinophil infiltration in the
esophagus. EoE is currently defined as the presence of
more than 15 intraepithelial eosinophils per high-
powered field (eos/HPF) in both the proximal and distal
esophagus [14]. Endoscopy of the subjects often shows
signs of longitudinal linear furrows, trachealization,
white plaques, and strictures but usually with a negative
pH probe result. Subjects with more severe disease sta-
tus present with severe stricturing, furrowing, and/or
trachealization, which may lead to mechanical dilation
of the esophagus or food impaction that requires
surgical removal [13].
EoE diagnosis can only be made through endoscopy
and biopsy of esophageal tissue. Prognostic tests that are
easily obtained and efficiently run through minimally
invasive techniques to predict disease progression are
lacking. Current guidelines suggest continual biopsies
for monitoring of disease progress and treatment effi-
ciency [15]. Since endoscopy with biopsy entails risks to
patients, we aimed to study immune indicators found in
plasma as secreted proteins that correlate with local pre-
sence in esophageal tissues in EoE subjects as compared
to controls. Moreover, we hypothesized that through the
discovery of specific EoE immune indicators, we could
further interrogate pathological mechanisms of EoE dis-
ease. Specifically, we focused on examining immune
indicators associated with EoE, for example, eotaxin and
FGF. FGF is a protein involved in cell development, cell
differentiation and tissue repair [16]. Additionally, bFGF
has been shown to enhance the half-life of cells [17] and
both bFGF and eotaxin coordinate their activity through
the activation of ERK [18,19]. Thus, in particular, we
hypothesized that FGF could enhance activation and
half-life of eosinophils in local esophageal tissues as
compared to peripheral blood.
Altogether, the data presented here provide a mechan-
istic explanation for how basic fibroblast growth factor
could worsen the pathogenesis of EoE by enhancing
activation of eosinophils through synergy with eotaxin
via the ERK signaling pathway. The data may be used in
the possible diagnosis and prognosis of EoE. In addition,
our results could provide an explanation for increased
eosinophil numbers, and prolongation of eosinophil
half-life in EoE disease pathology.
Methods
Human Clinical Data collection
The study was approved by the Stanford Administrative
Panel on Human Subjects in Medical Research. All
subjects signed informed consent forms before partici-
pating in the study. The study was performed according
to Declaration of Helsinki guidelines. Proximal and dis-
tal esophageal tissue and peripheral blood were obtained
from subjects during a diagnostic endoscopy and subse-
quent biopsy. Middle esophageal biopsy tissue was also
obtained from some patients. Biopsy samples were pre-
served as formalin-fixed and paraffin-embedded sections.
Histological diagnosis of EoE, GERD, or other disorders
(i.e, ulcerative colitis and Crohn’s disease) was made by
a licensed and certified clinical pathologist in gastroen-
terology at Stanford University School of Medicine Clin-
ical laboratory using guidelines by calculating the mean
number of eosinophils per high power field (HPF) in
more than 3 areas per biopsy sample [7]. Subjects who
had no pathological basis for symptoms and who had a
n e g a t i v ep Hp r o b ew e r ec o n s i d e r e dh e a l t h yc o n t r o l s
(HCs). Subjects who had a negative pH probe result and
whose histological sections contained greater than
15 eos/HPF were diagnosed with EoE as per guidelines
[14,20]. All EoE subjects had failed a trial of proton
pump inhibitor therapy (specifically, for an average of
6-8 weeks of therapy) before being diagnosed with EoE.
Subjects with a positive pH probe test and a negative
biopsy result were diagnosed with GERD. GERD sub-
jects had less than 6 eosinophils/HPF in the esophagus
on biopsy. Subjects labeled as “treated EoE” were con-
firmed with biopsies of esophagus showing improvement
(less than 5-10 eosinophils/HPF) and demonstrated
resolution of clinical symptoms. Subjects with eosino-
philic gastritis, eosinophilic colitis, acute or chronic
infections (viral, bacterial or fungal), autoimmune dis-
ease, or neoplasm were excluded from the EoE, HC, and
GERD groups. Allergic subjects were defined as having
a total serum IgE of >25 IU/ml and positive skin prick
testing as compared with positive histamine control to
foods. Patients were not allergy patch-tested routinely.
None of the subjects had active infections and no sub-
jects had positive findings for parasitic infections. Over-
all, samples were obtained on newly diagnosed EoE
(n = 35), treated EoE (n = 9), GERD (n = 8), ulcerative
colitis (UC, n = 5), and Crohn’s disease (CD, n = 5),
healthy controls (n = 8) respectively. Demographics for
each subject are found in Additional File 1, Table S1.
Plasma and PBMC separation
Each blood sample was centrifuged at 1800 RPM for
10 minutes, and the supernatant plasma layer was
collected and centrifuged for another 10 minutes at
13,000 RPM. Plasma was stored in 250 μla l i q u o t sa t
-80°C. Phosphate-buffered saline (PBS) was added to the
remaining blood cell layer until the total volume was
double the original collected blood volume. The homo-
geneous PBS-blood mixture was layered over the Ficoll
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ratio and subsequently centrifuged at 2200 RPM for
20 minutes. The peripheral blood mononuclear cell
(PBMC) layer was removed and washed twice with PBS
at 1800 RPM for 5 minutes. PBMCs were then re-
suspended at 1 million cells per milliliter in a solution
of 90% FBS and 10% DMSO and stored for later use for
QT-PCR.
Fluid Assays
Plasma samples underwent testing with Luminex 35-plex
technology (Invitrogen, Carlsbad, CA). 35 cytokines and
chemokines were assayed: fibroblast growth factor basic
(bFGF or FGF-2); eotaxin (1, 2, and 3); IL-1a; IL-1b; IL-1
receptor antagonist (IL-1RA); IL-2; IL-4; IL-5; IL-6; IL-7;
IL-8; IL-10; IL-12-p40; IL-12-p70; IL-13; IL-15; IL-17; IL-
17F; epithelial cell-derived neutrophil-activating protein-
78 (ENA78); granulocyte colony-stimulating factor
(G-CSF); granulocyte-macrophage colony-stimulating fac-
tor (GM-CSF); growth-related oncogene-alpha (GRO-a);
interferon-gamma (IFN-g); interferon-inducible protein
10 (IP10); leptin; monocyte chemotactic protein-3 (MCP-
3); monokine induced by gamma interferon (MIG);
macrophage inflammatory protein 1 alpha (MIP-1a);
macrophage inflammatory protein 1 beta (MIP-1b); nerve
growth factor (NGF); platelet-derived growth factor-BB
(PDGF-BB); regulated upon activation, normal T cell
expressed and secreted (RANTES); transforming growth
factor beta (TGF-b); tumor necrosis factor alpha (TNF-a);
tumor necrosis factor beta (TNF-b), and vascular endothe-
lial growth factor (VEGF). Samples were tested and nor-
malized with standard curves to ensure consistency and
calibrations occurred before each run, per manufacturer’s
instructions (Luminex Technologies, Invitrogen, Carlsbad,
CA). Furthermore, each sample was run in duplicate for
quality control. In addition, some plasma samples (n = 10)
from subjects were run through Cytometric Bead Array
(CBA) Multiplex technology (BD Biosciences, San Jose,
CA; Th1/Th2 cytokine Assay, used per manufacturer’s
instructions) to test the reproducibility of the Luminex
35-plex technology. For those cytokines tested (i.e.,
eotaxin-3, basic fibroblast growth factor (bFGF), G-CSF,
IFN-, IL-17, IL-1a, IL4, IL-5, macrophage inflammatory
protein 1a, and nerve growth factor), similar results were
obtained with CBA and Luminex technologies.
Immunohistochemistry
Paraffin-embedded tissue samples were soaked in xylene
and then solutions of 100%, 95%, and 70% ethanol
sequentially to remove the paraffin wax. Antigen
unmasking was performed by heating the slides in a
decloaking chamber to 120°C in Diva Decloaking buffer
(Biocare Medical, Concord, CA), and then cooling to
room temperature. H2O2 block (Lab Vision, Fremont,
CA) and protein block (Dako, Glostrup, Denmark) were
then applied to the tissue to prevent non-specific bind-
ing and block endogenous peroxidases. Unconjugated
mouse anti-human FGF-9 primary antibody (Clone D-8)
(Santa Cruz Biotechnology) was diluted 1:50 and applied
for 2 hours at 25°C. After washing, a secondary MACH
2 Mouse HRP (Biocare Medical, Concord, CA) antibody
was applied for 30 minutes. After further washing, the
slides were stained with DAB (Vector Labs, Burlingame,
CA) and subsequently counterstained with hematoxylin
before being mounted. Cells were counted per high-
powered field (HPF, 400×) at three different sites in the
tissue and the mean HPF was calculated. Polyclonal
unconjugated rabbit anti-human FGF-2 primary anti-
body (Abcam, Cambridge, MA) was diluted 1:250 with
antibody diluent (Dako, Glostrup, Denmark) and was
double-stained with mouse anti-human EG2 primary
a n t i b o d y( g i f to fD r .R e i n h a r dB .R a g g a m ) .AM A C H2
Double Stain HRP-AP secondary antibody (Biocare
Medical, Concord, CA) was used.
QT-PCR RNA analysis
PBMCs from each subject were used for QT-PCR RNA
analysis. For cDNA synthesis, 500 ng total RNA was
transcribed with cDNA transcription reagents (Applied
Biosystems, Foster City, CA) using random hexamers,
according to the manufacturer’s instructions. Gene
expression was measured in real-time with the Gen-
eAmp 7900 Sequence Detection System (Applied Biosys-
tems, Foster City, CA) using primers and other reagents
purchased from Applied Biosystems. Relative quantifica-
tion was measured using the Comparative CT
(Threshold Cycle) method. The expression level of a
gene in a given sample was represented as 2
-ΔΔ Ct where
ΔΔCT = [ΔCT(experimental)]-[ ΔCT(medium)]a n dΔCT =
[CT(experimental)]-[ C T (housekeeping)]. All PCR assays were
performed in triplicate. 100 ng of total isolated RNA
was submitted to reverse transcription (Invitrogen,
Carlsbad, CA). 50 ng of resulting cDNA was submitted
to TaqMan™PCR on an ABI Systems qPCR machine
(Applied Biosystems, Foster City, CA) at the Stanford
Department of Pediatrics QT-PCR Facility using gene-
specific, fluorochrome-labeled probe/primer sets pur-
chased from Applied Biosystems, Inc. EoE, GERD, HC,
UC, and CD samples were tested for fibroblast growth
factor (FGF), fibroblast growth factor receptor (FGF-R),
eotaxin, C-C chemokine receptor type 3 (CCR3), extra-
cellular signal-regulated kinase (ERK), c-Jun N terminal
kinase (JNK), IL-13, IL-5, Fas, B cell lymphoma protein
2 (Bcl-2), and normalized to the b-2-microglobulin gene.
Statistics
Statistical analysis was performed with the GraphPad
Prism software (GraphPad Software, La Jolla, CA).
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formed using the one-way analysis of variance
(ANOVA) non-parametric Kruskal-Wallis test and the
Dunn’s Multiple Comparison post-test. Differences were
considered significant at a p-value of less than or equal
to 0.05. Correlation analysis between fold expressions
was performed using the Spearman correlation.
Results
Demographics
Data were analyzed from newly diagnosed EoE (n = 35),
treated EoE (n = 9), GERD (n = 8), ulcerative colitis
(UC, n = 5), and Crohn’s disease (CD, n = 5), healthy
controls (HC, n = 8) respectively. Demographics for
each subject are found in Additional File 1, Table S
1. Consistent with past findings, EoE seemed to parti-
cularly affect males (25/35 subjects). Subjects (71%) had
elevated IgE levels and positive prick skin testing to at
least one food allergen (performed at the Stanford
Allergy and Immunology Clinics). None of the UC or
CD subjects were on medications at the time of biopsy
since these were representative newly diagnosed subject
biopsies for the UC and CD subjects.
Prior to the subjects’ endoscopy for possible diagnosis
of EoE, subjects had been treated with anti-reflux ther-
apy for 6-8 weeks without a positive response. Seven
subjects were treated with only swallowed budesonide, 6
were treated with only swallowed fluticasone, 3 were
treated with only an elimination diet, 6 were treated
with only an elemental diet, and 11 were treated with
both swallowed budesonide and an elimination diet
(Additional File 1, Table S2).
QT-PCR Assays demonstrate differential expression of
immune indicators in EoE
RNA purified from subject PBMCs was used for QT-
P C Ra s s a y s .T r a n s c r i p t sf o rb F G Fw e r ef o u n dt ob e
increased in newly diagnosed EoE subjects and expres-
sion was decreased after treatment. QT-PCR data
showed that untreated EoE subjects had an increased
expression of bFGF that was up to eight-fold higher
(n = 35) compared to the HCs (n = 8, 1×, p < 0.05), and
compared to when on treatment (n = 9 EoE subjects,
1.5×, p < 0.001). Although FGF levels in GERD subjects
were slightly elevated (n = 8), it was not statistically
s i g n i f i c a n tc o m p a r e dt oH C( p>0 . 0 5 )( F i g u r e1 a ) .E o E
subjects had statistically significant increased FGFR2
expression compared to HC (14×, p < 0.05) (Figure 1a).
EoE subjects had a slight but not statistically significant
increase in eotaxin-3 expression when compared to
G E R D( 2 × ,p>0 . 0 5 )a n dt oH C( 6 × ,p>0 . 0 5 )( F i g u r e
1b). Eotaxin-1 and 2 transcripts were also assessed and
found similar to eotaxin-3 expression patterns (data not
shown). CCR3, the eotaxin-3 receptor, also had an
increased expression factor of 2× compared to GERD
and HC (Figure 1b). IL-5 expression was a six-fold
increase in EoE subjects versus GERD and a three-fold
increase versus HC (Figure 1c). However, the difference
was not statistically significant. IL-13 had a statistically
significant seven-fold increase in EoE subjects versus
H C( p<0 . 0 5 )a n da3 . 5f o l di n c r e a s eo v e rG E R Ds u b -
jects (p < 0.001) (Figure 1c). IL-13 increases were asso-
ciated with EoE subjects with concomitant food allergies
(data not shown).
In summary, specific immune indicators with increased
expression in newly diagnosed EoE compared to treated
EoE, HC, GERD, UC, and CD were: bFGF, FGF-Receptor
2, IL-13, IL-5, eotaxin, and CCR3 (in order of highest to
lowest extent of increased transcript expression). Inter-
estingly, upon examination of transcript expression of
signaling pathway proteins and apoptosis-related proteins
such as ERK, JNK, Bcl-2, caspase 8, and Fas, for the newly
diagnosed EoE subjects, it was found that the signaling
pathway transcripts of ERK but not JNK were found to
be increased relative to HC, UC, CD and treated EoE
(Figure 1d). ERK was expressed at a minimum of four-
fold increase at statistically significant differences com-
pared to all other subjects (p < 0.05) (Figure 1d). The
extent of the increases in ERK was correlated with bFGF
increases in expression (R = 0.89, p < 0.05) (Figure 2a)
and with eotaxin increases in expression (R= 0.82,
p < 0.05) (Figure 2b). This suggests that FGF signaling
could occur through ERK but not JNK, and that this sig-
naling could enhance the ERK-dependent signaling path-
ways associated with eotaxin. EoE subjects had a 3-fold
increase in Bcl-2 expression compared to treated EoE
patients while caspase 8 showed a 3-fold decrease
(p < 0.05) (Figure 1e). Likewise, there was a 3-fold
decrease in Fas expression levels in EoE subjects com-
pared to the treated EoE subjects (p < 0.05) (Figure 1f).
Fluid Assays on plasma show highly elevated bFGF
specifically in EoE subjects
Since we found bFGF and other immune indicators to be
specifically increased in PBMCs of EoE subjects, we then
performed fluid assays to determine whether they were
present systemically in the plasma. Our fluid assay data
(performed via Luminex 35-plex technology per manufac-
turer’s instructions, Invitrogen and via Cytometric Bead
Array Technology per manufacturer’s instructions, BD
Biosciences) were important in the narrowing of potential
immune indicators specific to eosinophilic esophagitis. In
plasma from HC subjects (n = 10), bFGF levels were low
(mean 0.13 pg/mL, s.e. 0.09 pg/mL) while bFGF was sig-
nificantly upregulated in EoE subjects (n = 10, mean 81.98
pg/mL, s.e. 17.23 pg/mL for EoE, p < 0.05). Differences in
bFGF levels between EoE and GERD were also significant
(n = 10, mean 1.74 pg/mL, s.e. 0.64 for GERD, p < 0.05)
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cant decrease in bFGF (n = 9, mean 4.60 pg/mL, s.e. 1.35
pg/mL, p < 0.05) (Figure 3a). Treated EoE subjects were
the same subjects as the EoE subjects. A decrease in bFGF
was seen in all subjects. There was a significant difference
in the level of peripheral IL-5 in EoE subjects compared to
HC (p < 0.05), GERD (p < 0.05), and EoE treated
(p < 0.05) (Figure 3b). Other cytokines that showed statis-
tically significant differences between HC and EoE subjects
include G-CSF, GRO-a.I F N - g, IL-15, IL-13, IL-17, IL-2,
IP-10. MIG, MIP-1a,M I P - 1 b,N G F ,a n dR A N T E S( d a t a
not shown).
Figure 1 a-f The fold expression of immune indicators bFGF, FGF-R, Eotaxin-3, CCR3, IL-5, IL-13, ERK, JNK, Bcl-2, Capase 8, and Fas.a )
EoE subjects statistically significant increases in levels of bFG and FGFR2 (p < 0.001) There was an 8-fold increase in the bFGF levels in EoE
subjects as compared to HC subjects and a 4-fold increase compared to GERD; b)There was a 6-fold increase in eotaxin-3 comparing EoE
subjects to HC and a 2-fold increased when compared to GERD subjects. However, this was not statistically significant. CCR3 levels were
consistent among all subject groups; c) There was a statistically significant increase in the amount of IL-5 in subjects with EoE as compared to
GERD (p < 0.01). Increase in IL-13 in EoE was statistically significant compared to all other subject groups (p < 0.001); d) ERK was high increased
compared to other subjects groups (p < 0.001) while JNK levels remained consistent; e) EoE subjects had a 3-fold increase of Bcl-2 and a 3-fold
decrease in caspase 8 expression compared to treated EoE subjects (p < 0.05); f) Fas expression was down-regulated by 3-fold in EoE subjects as
compared to treated EoE subjects (p < 0.05). EoE: Eosinophilic Esophagitis; GERD: gastroesophageal reflux disease; HC: healthy control; UC:
ulcerative colitis; CD: Crohn’s disease.
Figure 2 a There is a positive correlation between the fold expression of bFGF and ERK, suggesting that the upregulation of bFGF
may also influence the upregulation of ERK. Figure 2b: There is a positive correlation between the fold expression of ERK and eotaxin-3.
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To test whether there were increases in expression of
FGF in the local tissue of the esophagus in EoE com-
pared to controls, immunohistochemistry (IHC) using
the FGF antibody was conducted on slides from HC
subjects (n = 7), GERD subjects (n = 6), and EoE sub-
jects (n = 7). Cells were counted at 400× (Figure 4). EoE
subjects were verified to have more than 15 eos/HPF as
shown by EG2 antibody staining. HCs showed no cells
surrounded by FGF, and there was only a minimal pre-
sence in GERD subjects. EoE subjects, however, consis-
tently showed FGF in significantly higher counts
c o m p a r e dt oe i t h e rG E R D( p<0 . 0 5 )o rH C( p<0 . 0 5 )
(Figures 4, 5 and 6), based on an average of three areas
per slide. The antibody was not guaranteed to be
isoform-specific.
Discussion
Our data indicate that fibroblast growth factor is among
a set of factors that are differentially regulated in the
periphery in EoE, suggesting that eosinophilic esophagi-
tis is not only a local condition but also a systemic dis-
order that may be detected through analysis of plasma
samples. Although symptoms of disease of may be loca-
lized at just the esophagus, our results show that EoE
subjects have a set of unique peripheral immune indica-
tors that could be used as diagnostic indicators. In addi-
tion, through analysis of PBMCs (which consist mainly
of lymphocytes, monocytes, macrophages, and dendritic
cells rather than granulocytes), we were able to detect
an activation state present in other immune cells in EoE
that could lead to subsequent activation of eosinophils.
This would prove especially useful since current diagno-
sis involves an esophageal tissue biopsy, which carries
potentially unnecessary risks.
T h ep l a s m af l u i da s s a yd a t ap r o v i d e dh e r es h o wt h a t
bFGF was upregulated in EoE subjects. Along with
bFGF upregulation, an increase in eotaxin was also seen
in EoE subjects. Interestingly, IL-5 was increased in the
plasma of EoE subjects compared to that of GERD or
HC. The subject with the highest IL-5 expression level
Figure 3 a) EoE subjects had an elevated level of bFGF in comparison (p < 0.05) to those of HC, GERD, and treated EoE subjects
(same subjects as EoE subject but now on therapy); b)IL-5 was also elevated in EoE subjects compared to treated EoE subjects (p <
0.05) and gastroesophageal reflux disease and healthy control subjects (p < 0.05). (*p < 0.05).
Figure 4 The number of cells that are FGF positive cells are
significantly greater in EoE subjects than in HC (p < 0.05) or
GERD (p < 0.05). (* p < 0.05).
Figure 5 IHC at 400× with FGF staining (representative EoE
subject).
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(10.2%). Further work on the role of individual immune
indicators vs. a composite biomarker tool using bFGF,
eotaxin, and IL-5 simultaneously in blood samples from
EoE vs. GERD vs. HC could be studied. Recent studies
have also shown that IL-13 is overexpressed in the eso-
phagus of EoE patients [20-22].
Recently, Mulder et al. found increased FGF-9 and
FGF-Receptor expression levels in tissue from EoE sub-
jects (n = 7) compared to HC (n = 7) and GERD
(n = 7). However, there was no analysis of FGF expres-
sion in plasma or peripheral blood mononuclear cells.
There was no evaluation of other FGF isoforms [23].
Moreover, a possible link to the mechanism of EoE
pathology was still to be identified.
The fibroblast growth factor (FGF) family consists of
22 members that are essential to normal cell develop-
ment, cell differentiation, and tissue repair after injury.
The receptors for FGFs (FGFR) are tyrosine kinase
receptors that are specific for particular FGF subsets
and can be found in a variety of tissues, including
epithelial and mesenchymal tissue [20]. bFGF increases
the half-life of cells and could possibly increase the
overall lifetime of the eosinophil in the esophagus [17].
Our data showing that the antiapoptotic pathways are
associated with EoE confirm this possibility. Eosinophils
are also known to secrete bFGF [23] and FGF-9 [24]
upon the presence of necrotic epithelial cells. bFGF is
also known to be secreted in case of cellular damage,
such as the esophageal epithelial tissue damage experi-
enced by EoE subjects [12]. Both eotaxin and bFGF
mediate their biological effects through the ERK path-
way [18,19]. Our data showed an increased expression
of ERK in the PBMC of EoE subjects, and it is possible
that, together with eotaxin, FGF enhances activation of
eosinophils in EoE specifically.
The increased global expression of bFGF led to the
investigation of the local expression bFGF of the eso-
phageal biopsies of the subjects. Our data show that
FGF, as assessed by IHC of local tissue and bFGF
assessed by QT-PCR of PBMC, are upregulated in EoE.
Initial immunohistochemistry antibody stains of FGF
demonstrate an increase in local esophageal FGF expres-
sion levels in the lamina propria. FGF is diffusely spread
over the lamina propria, close to the surface mucinous
epithelium and covers mucosal glands as well. While
healthy control and GERD subjects have very low
expression of FGF, EoE subjects show higher FGF
expression. It is important to note that bFGF and FGF-9
are highly homologous, sharing over 54% identical or
similar amino acids (Protein BLAST). Since the FGF-9
a n t i b o d yw a sm a d ea g a i n s tt h ee n t i r el e n g t ho ft h e
amino acid, it is likely that homologous isoforms of FGF
such as bFGF were also recognized. These data further
suggested that FGF expression levels may help differ-
entiate EoE from GERD, since EoE subjects have a
significantly higher FGF expression level than GERD.
bFGF may be involved in the esophageal tissue fibrosis
that is common to many EoE subjects. Past research has
demonstrated that bFGF is a pro-fibrotic cytokine that
may promote both fibrosis and angiogenesis by binding
to the extracellular matrix [25,26]. The release of FGF
by a wide variety of cells, especially in conditions of cel-
lular damage, may explain the high levels of systemic
FGF in EoE subjects. Additionally, FGF is irreversibly
bound to the extracellular matrix after its release,
further amplifying its fibrotic capabilities [26]. FGF may
be further upregulated in the repair response after injury
to the esophageal endothelium, leading to proliferation
of fibroblasts and resulting fibrosis.
It has been shown that recurrent stricture formation
and dysphagia can be associated with esophageal sube-
pithelial fibrosis [27]. Studies on animal models have
s h o w nt h a ts t r i c t u r ec a nf o r mi nt h ee p i t h e l i u mr e p a i r
process, leading to an overly dense extracellular matrix,
an overproduction of fibroblasts, and the development of
scar tissue. In comparison to a previous study showing
that EoE subjects have an increase in local FGF produc-
tion [25], our study demonstrates that there is increase in
FGF production locally and this increase is also reflected
systemically. In addition, the extent of increase in FGF
and ERK pathways was closely associated with the sever-
ity of the disease and endoscopic findings in the EoE
patients; further patients will help determine if FGF and
other immune indicators are correlated closely with EoE
disease. Interestingly, we did not detect a difference in
F G Fa n de o t a x i ne x p r e s s i o ni na t o p i c( a l l e r g i c )v s .n o n
atopic EoE patients. However, further studies are needed
to seek to identify possible pathological differences asso-
ciated with atopic vs. non atopic EoE.
Figure 6 IHC at 400× with FGF staining (representative GERD
subject).
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Page 7 of 9bFGF expression is essential to the transcription of
ERK [18] and ERK feeds into the eotaxin-3 pathway,
potentially further activating the eosinophil and improv-
ing its sensitivity and migra t i o nt o w a r d se o t a x i ni nt h e
esophageal tissue. Activation of ERK may induce both
degranulation and chemotaxis of eosinophils [19]. It does
appear that eosinophils also express bFGF [28]. The eosi-
nophils may be operating in a positive feedback loop in
which the expression bFGF is encouraging the increased
activation of the eosinophil, which then leads to more
bFGF expression and better chemotaxis. Additionally,
like bFGF, FGF-9 can activate both ERK1 and ERK2 [29].
F u r t h e ra n a l y s i so fm o r es u b j e c t si sn e c e s s a r yt oi d e n -
tify additional immune indicators that constitute a
unique EoE plasma protein composite or individual
marker profile. Lower esophageal eosinophilia is com-
mon in GERD, and further determination of numbers of
eosinophils in the tissues of GERD subjects is needed;
we believe our current results reflect a relative difference
in GERD and EoE subjects. We have focused on EoE to
determine the involvement of specific blood immune
indicators in the disease; we will continue to study other
eosinophilic gastroenterological disorders such as eosi-
nophilic gastroenteritis and eosinophilic colitis to deter-
mine the role of FGF in those disease entities.
We have demonstrated that fibroblast growth factors
may play an important role in the pathophysiology of
EoE and may be part of a set of immune indicators that
could, without biopsy, differentiate EoE subjects from
subjects with other clinically similar symptoms such as
GERD. In this effort to determine possible pathological
mechanisms, we found that FGF increase was associated
with activation of ERK and of anti-apoptotic, pathways
which could enhance eotaxin signaling and increase
eosinophil lifespan, respectively.
Conclusions
Subjects with eosinophilic esophagitis had different
immune indicator profiles, specifically with increases in
basic fibroblast growth factor in blood plasma, periph-
eral blood mononuclear cells, and local esophageal
tissue compared to subjects with gastroesophageal reflux
disease, ulcerative colitis, Crohn’s disease, and healthy
controls. The upregulation of fibroblast growth factor
was found to be associated with ERK expression, which
is in turn essential to the expression eotaxin-3, an eosi-
nophil chemoattractant. Additionally, increases in basic
fibroblast growth factor were found to be associated
with activation of anti-apoptotic pathways. Therefore,
FGF with eotaxin and antiapoptic factors could enhance
migration and prolong the life-span of eosinophil,
respectively. This may also explain the prolonged pre-
sence of higher than normal numbers of eosinophils in
the esophagus.
Additional material
Additional file 1: Supplementary tables. Table S1a: Demographics of
EoE patients. D (distal) and P (proximal) reflect location of the eosinophil
count. Eosinophil counts are given as per high powered field (> greater
than; = equal to). If negative for any allergies, total IgE less than 10 kU/
mL. Table S1b: Demographics of GERD patients Table S1c: Demographics
of healthy controls. Table S1 d. Demographics of Crohn’s disease and
ulcerative colitis patients. Table S2: Treatment emographics of EoE
subjects.
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